IL13 and acute myeloid leukemia: In clinical studies, it has been reported that tumor-activated ILC2s secreted IL-13 to induce M-MDSCs and support tumor growth, whereas ATRA treatment reversed the increase of ILC2-MDSCs in AML (26).